Glaxo filling gap in HIV portfolio via licensing agreement with Hoechst/Bayer for non-nucleoside RTI.
Executive Summary
GLAXO CONTINUES HIV THERAPY IN-LICENSING STRATEGY WITH HOECHST/BAYER AGREEMENT giving Glaxo Wellcome rights to develop and market the quinoxaline class of non-nucleoside reverse transcriptase inhibitors discovered as part of a research collaboration between Hoechst Marion Roussel and Bayer. Under the Feb. 12 agreement, Glaxo will make an upfront payment to Hoechst and Bayer, make a milestone payment for the first compound to reach the market and pay royalties on any product sales. The agreement is subject to antitrust review.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth